新生儿黄的高剂量或低剂量光疗
Nai Ming Lai1, Azanna Ahmad Kamar2, Shaun Wen Huey Lee3
1School of Medicine, Taylor's University, Subang Jaya, Malaysia.
The Cochrane database of systematic reviews
|March 5, 2026
概括
对新生儿黄的高剂量光疗显示,对于严重的结局,如和脑,有不确定的益处. 虽然它可能会略微降低胆红素水平,但需要更强大的试验来确认临床意义和安全性.
科学领域:
- 新生儿医学 新生儿医学
- 儿科神经学 儿科神经学
- 基于证据的医学基于证据的医学.
背景情况:
- 光疗是新生儿高 bilirubinaemia (黄) 的主要治疗方法.
- 增加光疗强度或剂量是高胆红素水平的常见情况,但其益处和安全性尚不确定.
研究的目的:
- 评估高剂量与低剂量光疗对婴儿胆红素水平的影响.
- 评估对Kernicterus谱系障碍 (KSD) 疾病的影响,包括急性胆红素脑病,Kernicterus,脑和神经发育障碍.
主要方法:
- 随机对照试验 (RCT),准RCT和集群RCT的系统审查和元分析.
- 在主要数据库中进行的搜索,包括Medline,Embase和CENTRAL,截至2025年6月.
- 包括患有需要光疗的高 bilirubinaemia 的满期和早产婴儿;高剂量 (光谱辐射> 30 μW/cm2/nm) 与低剂量 (< 30 μW/cm2/nm) 的比较.
主要成果:
- 低至非常低的确定性证据排除了关于高剂量光疗对急性胆红素脑病变,脑和死亡率的影响的确结论.
- 没有研究评估了kernicterus. 高剂量光疗可能在24小时和48小时内略有降低血清胆红素,但临床意义尚不清楚.
- 在几个结果中观察到显著的异质性,解释不充分,导致证据确定性降低.
结论:
- 目前的证据不足以确定新生儿黄高剂量光疗的益处或风险.
- 需要进一步进行高质量的RCT来研究不同光疗剂量的疗效和安全性.
- 未来的研究应该专注于强大的方法,并包括患者重要的结果,以澄清临床益处.
相关概念视频
01:14Changes in Skin Color: Clinical Perspectives
4.0K
The first thing a clinician sees is the skin, so the examination of the skin should be part of any thorough physical examination. Most skin disorders are relatively benign, but a few, including melanomas, can be fatal if untreated. A couple of the more noticeable disorders, albinism and vitiligo, affect the appearance of the skin and its accessory organs.
Albinism
Albinism is a genetic disorder that affects (completely or partially) the coloring of skin, hair, and eyes. The defect is primarily...
Albinism
Albinism is a genetic disorder that affects (completely or partially) the coloring of skin, hair, and eyes. The defect is primarily...
4.0K
01:29Drug Dosing: Infants and Children
555
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
555
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
303
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
303